|
rs2273535
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
For esophageal cancer, the AurkA Phe31-Ile polymorphism has previously been associated with tumor progression.
|
29560108 |
2018 |
|
rs1284806277
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs1284806277
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Stable S100P knockdown CRC cell lines were established to elucidate the relationship between S100P expression and tumor progression in vitro and in vivo.
|
26975699 |
2016 |
|
rs969139366
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.
|
28541695 |
2017 |
|
rs961150162
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs9282861
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs869320694
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs773862672
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs77375493
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
|
23558526 |
2013 |
|
rs767808984
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs762807774
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
|
29679610 |
2018 |
|
rs727503094
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs720012
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two linked SNPs (rs2073778 and rs720012) in DGCR8 showed significant association with tumor progression (HR = 4.00, 95% CI = 1.53-10.46, P = 0.005).
|
23322153 |
2013 |
|
rs7121
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this review and meta-analysis, we focus on the synonymous SNP rs7121 (<i>FokI</i>, c.393C>T), which is associated with either tumor progression or prolonged survival in cancer patients (overall hazard ratio = 2.256; p < 0.001).
|
31124412 |
2019 |
|
rs587782529
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.
|
9704931 |
1998 |
|
rs587782148
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Sequencing of margins with dysplasia demonstrated an identical nonconservative mitochondrial mutation (A76T in ND4L) as the tumor, suggesting a role of mtDNA mutation in tumor progression.
|
17456604 |
2007 |
|
rs562015640
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs55958994
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
|
31328168 |
2019 |
|
rs557263543
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
|
rs4987188
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and cancer progression.
|
16252083 |
2005 |
|
rs4986791
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Caco-2 cells that expressed TLR4-D299G underwent the epithelial-mesenchymal transition and morphologic changes associated with tumor progression, whereas cells that expressed wild-type TLR4 or TLR4-T399I did not.
|
21920464 |
2011 |
|
rs4986790
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
TLR4-D299G induces features of neoplastic progression in intestinal epithelial Caco-2 cells and associates with aggressive colon cancer in humans, implying a novel link between aberrant innate immunity and colonic cancerogenesis.
|
21920464 |
2011 |
|
rs4880
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The current data, based on a large cohort (n = 929) of Chinese patients with gastric cancer, suggested that the presence of SOD2 rs4880 and GSTP1 rs1695 genotypes may contribute to cancer progression as well as tumor aggressiveness.
|
22517484 |
2012 |
|
rs4444235
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
LOH analysis suggested that the three CRC risk variants, rs12657484, rs3802842, and rs4444235, exhibited somatic allele-specific imbalance and might be critical during neoplastic progression.
|
24968322 |
2014 |
|
rs438034
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
In addition, the 52 single nucleotide polymorphisms associated at P<10(-4) included rs438034 (CENPF; P=4.86×10(-6)), previously correlated with cancer progression, and rs2255235 (B2M; P=3.10×10(-5)) and rs2064501 (IL22RA2; P=4.81×10(-5)) which map to B-cell genes.
|
21659360 |
2011 |